Saim Korlu

Senior Advisor

Career Highlights 

Prospera Capital Partners 

  • Advised Sestek, an AI-powered conversational technology pioneer, on its 100% cross-border sale to Unifonic Inc., a communications platform as a service (CPaaS) provider
  • Advised DAIO Corp., a $4.0 bn Japanese corporation, on its cross-border acquisition of SCA-Yildiz Hygiene Products for $35 mn. Led the post-merger integration of the acquired business

PineBridge Investments 

  • Originated and led the acquisition of a chemicals/mining and paper group for $200mn
  • Sourced and led $30mn of equity investment in Alcazar Energy, a solar energy firm
  • Acted as a Director on the Board of Ulusal Finance, a factoring loan company; helped generate 66% growth in assets to $275mn in 2 years and raise $13mn financing from the EBRD

Actera Group

  • Sourced and completed the acquisition of Celebi Aviation Group for $500mn
  • Originated and led the execution of deals for NitroMak Explosives (chemicals) for $165mn; and EuroDrip Irrigation (agriculture) for $140mn

Abraaj Capital

  • Oversaw the fund’s $500mn investment in Acibadem Healthcare (hospitals and insurance) and oversaw add-on acquisitions/JVs in Egypt, Bahrain, and Russia
  • Led the evaluation and negotiation of a $1.6bn deal for an oil & gas company

J.P. Morgan

  • Completed over 25 M&A transactions worth over $16 bn and raised debt and equity financings worth over $12bn
  • Promoted multiple times and became one of the youngest revenue-generating Vice Presidents
  • Built domain expertise in multiple segments of the healthcare industry, including pharmaceuticals, biotech, medical technology & devices, health insurance, hospitals, and IT

The Carlyle Group

  • Led the execution of all private equity investment activities in the healthcare industry
  • Led the acquisition of Talecris Pharma and raised $100mn of acquisition debt financing
  • Monetized Carlyle’s investment in Empi Inc, a medical device company, generating shareholder gains of $140mn
  • Completed InteliStaf’s $50mn acquisition of Star-Med
  • Completed MedPointe Pharma’s in-licensing agreement for a $200mn drug from AstraZeneca

Interests

Outside of the office Saim is a History buff and an avid snowboarder.